Monday, September 23, 2013
New requirements from FDA
mean companies will have to do at least five postmarket studies for long-acting
and extended-release opioids. But first, sponsors and the agency must iron out
the details, including the endpoints, size and duration of the studies.
In the meantime, the agency has
proposed label changes intended to curtail use of the products until the safety
data are available.